{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T04:28:05Z","timestamp":1710563285056},"reference-count":21,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T00:00:00Z","timestamp":1237852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Sitaxentan inhibits the metabolism of warfarin, resulting in a need for adjustment of warfarin dose when both drugs are coadministered. We report the long\u2010term effects on bleeding of acenocoumarol co\u2010administered as part of conventional therapy for pulmonary hypertension with sitaxentan in a subset of patients enrolled in the Sitaxentan To Relieve ImpaireD Exercise\u20103 (STRIDE\u20103) study.<\/jats:p><jats:p><jats:bold>Materials and methods\u2002<\/jats:bold> STRIDE\u20103 is an ongoing, long\u2010term, open\u2010label trial, evaluating the safety and efficacy of sitaxentan, 100\u2003mg once daily, in patients with pulmonary arterial hypertension. Information on bleeding events was collected prospectively, including the type of event, severity, anticoagulant use and investigator attribution of causality. Coagulation tests were performed on a monthly basis. A clinically significant interaction was defined as an international normalized ratio (INR) \u2265\u20035\u00b70, or any minor bleeding event <jats:italic>plus<\/jats:italic> an INR &gt;\u20032\u00b70 and &lt;\u20035\u00b70.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Of 55 patients enrolled in STRIDE\u20103, 50 received acenocoumarol. Average follow\u2010up was 158\u00b76\u2003\u00b1\u200357\u00b76\u2003weeks. The average dose of anticoagulant therapy was 3\u00b79\u2003\u00b1\u20031\u00b73\u2003mg\u2003week<jats:sup>\u22121<\/jats:sup> (range, 1\u00b75\u20137\u00b70\u2003mg\u2003week<jats:sup>\u22121<\/jats:sup>). Following treatment, an INR \u2265\u20035 in at least one INR determination was observed in 13 patients, although none of these patients had a clinically significant bleeding event. Dose reductions in acenocoumarol were performed to adjust target INR to 1\u00b75\u20132\u00b70. Two patients died of massive haemoptysis, but these episodes were not attributed to a drug interaction. Four patients with an INR &gt;\u20032\u00b70 and &lt;\u20035\u00b70 experienced a minor bleeding event (nosebleeds\/gingivitis).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> No clinically significant bleeding events were recorded with coadministration of sitaxentan and acenocoumarol in this patient subgroup. These results suggest that coadministration of sitaxentan and acenocoumarol is clinically manageable and well tolerated.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2009.02116.x","type":"journal-article","created":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T10:51:01Z","timestamp":1237891861000},"page":"14-18","source":"Crossref","is-referenced-by-count":7,"title":["Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension"],"prefix":"10.1111","volume":"39","author":[{"given":"T.","family":"Pulido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Roquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. T.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lupi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,3,24]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.09.014"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00015206"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.3.841"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.80.5.1198"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.70.4.580"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200307-957OC"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.01.057"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.fjc.0000166207.74178.d0"},{"issue":"1","key":"e_1_2_8_10_2","first-page":"307A","article-title":"Sitaxsentan improves time to clinical worsening in patients with pulmonary arterial hypertension","volume":"4","author":"Oudiz R","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008380"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-006-9022-7"},{"key":"e_1_2_8_13_2","first-page":"397","article-title":"Cytochrome P450 2C9 polymorphism and acenocoumarol therapy","volume":"64","author":"Mark L","year":"2006","journal-title":"Kardiol Pol"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544120-00003"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.037"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-7-199304010-00005"},{"key":"e_1_2_8_18_2","volume-title":"The Perpetrator Potential of Sitaxentan: Human CYP Enzyme Induction","author":"Stavros F","year":"2008"},{"key":"e_1_2_8_19_2","unstructured":"Thelin (sitaxentan). Summary of Product Characteristics. Encysive (UK) Limited. January 2008."},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E566"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2006.12.045"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1668OC"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2009.02116.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2009.02116.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T02:50:05Z","timestamp":1694400605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2009.02116.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,24]]},"references-count":21,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1365-2362.2009.02116.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2009.02116.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,24]]}}}